Panagora Asset Management Inc. Purchases 144,936 Shares of Phreesia, Inc. $PHR

Panagora Asset Management Inc. grew its position in shares of Phreesia, Inc. (NYSE:PHR) by 134.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 252,354 shares of the company’s stock after purchasing an additional 144,936 shares during the quarter. Panagora Asset Management Inc. owned approximately 0.42% of Phreesia worth $7,182,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Farther Finance Advisors LLC grew its position in Phreesia by 9,375.0% during the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock valued at $86,000 after acquiring an additional 3,000 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Phreesia by 53.0% in the 1st quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company’s stock valued at $137,000 after purchasing an additional 1,825 shares in the last quarter. Entropy Technologies LP bought a new position in shares of Phreesia during the 1st quarter valued at $202,000. AlphaQuest LLC grew its holdings in shares of Phreesia by 294.8% during the 1st quarter. AlphaQuest LLC now owns 8,216 shares of the company’s stock valued at $210,000 after purchasing an additional 6,135 shares during the last quarter. Finally, Virtus Advisers LLC purchased a new position in Phreesia in the 1st quarter worth $235,000. Institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. BMO Capital Markets initiated coverage on Phreesia in a research note on Thursday, November 13th. They set an “outperform” rating and a $32.00 price objective on the stock. DA Davidson raised their price target on Phreesia from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. KeyCorp lowered their price objective on Phreesia from $35.00 to $32.00 and set an “overweight” rating for the company in a research report on Wednesday, October 8th. Stephens restated an “overweight” rating and issued a $32.00 target price on shares of Phreesia in a report on Wednesday, September 3rd. Finally, Needham & Company LLC lifted their target price on shares of Phreesia from $29.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. Fourteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Phreesia has an average rating of “Moderate Buy” and an average price target of $33.86.

Phreesia Price Performance

Shares of Phreesia stock opened at $20.17 on Wednesday. The business has a 50 day moving average of $22.28 and a 200 day moving average of $25.38. Phreesia, Inc. has a 52 week low of $18.55 and a 52 week high of $32.76. The company has a market cap of $1.21 billion, a PE ratio of -48.02 and a beta of 0.74. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The business had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. During the same period in the previous year, the firm earned ($0.03) EPS. The company’s quarterly revenue was up 14.9% compared to the same quarter last year. As a group, equities research analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Insider Activity at Phreesia

In other Phreesia news, insider Evan Roberts sold 3,761 shares of Phreesia stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $87,556.08. Following the sale, the insider directly owned 726,837 shares of the company’s stock, valued at approximately $16,920,765.36. The trade was a 0.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Balaji Gandhi sold 4,183 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $97,380.24. Following the transaction, the chief financial officer owned 99,125 shares in the company, valued at $2,307,630. This trade represents a 4.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 26,174 shares of company stock valued at $603,835 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.